{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:32:41Z","timestamp":1790249561959,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>We aimed to perform a systematic review and meta-analysis of observational studies, primarily to compare laboratory findings, including liver function tests, and metabolic parameters, between patients with Metabolic and alcohol-related\/associated liver disease (MetALD) and those with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease (ALD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>MetALD is a newly recognized subtype of steatotic liver disease (SLD) characterized by the synergistic impact of metabolic dysfunction and alcohol consumption. Data on its clinical and laboratory profile remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Thirty-three studies including 7,504,674 individuals were analyzed. Compared to MASLD, MetALD was associated with higher aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), higher triglycerides (TG) and high density lipoprotein-cholesterol (HDL-C), lower low density lipoprotein-cholesterol (LDL-C), and higher systolic and diastolic blood pressure, but lower body mass index (BMI) and hemoglobin A1c (HbA1c). Compared to ALD, MetALD showed lower liver enzymes, while most metabolic parameters were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MetALD has distinct laboratory and metabolic features compared to MASLD, while differences with ALD are less pronounced. These findings favor MetALD as a distinct entity warranting further, more focused research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00696-6","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:21:15Z","timestamp":1772792475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Maria","family":"Tampaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chologkitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios \u0391.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"696_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"issue":"3","key":"696_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"key":"696_CR3","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2023","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023;80:e76\u20137.","journal-title":"J Hepatol"},{"key":"696_CR4","doi-asserted-by":"publisher","first-page":"156101","DOI":"10.1016\/j.metabol.2024.156101","volume":"163","author":"M Tampaki","year":"2025","unstructured":"Tampaki M, Tsochatzis E, Lekakis V, Cholongitas E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related\/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism. 2025;163:156101.","journal-title":"Metabolism"},{"issue":"6","key":"696_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, Calleja JL, Vilar-Gomez E, Iruzubieta P, Rodr\u00edguez-Duque JC, Del Barrio M, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81(6):930\u201340.","journal-title":"J Hepatol"},{"key":"696_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2017.11.006","volume":"68","author":"M Boyle","year":"2018","unstructured":"Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol. 2018;68:251\u201367.","journal-title":"J Hepatol"},{"issue":"3","key":"696_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","volume":"5","author":"JK Dyson","year":"2014","unstructured":"Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211\u20138.","journal-title":"Frontline Gastroenterol"},{"issue":"24","key":"696_CR8","doi-asserted-by":"publisher","first-page":"16226","DOI":"10.3390\/ijms232416226","volume":"23","author":"SDH Malnick","year":"2022","unstructured":"Malnick SDH, Alin P, Somin M, Neuman MG. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. Int J Mol Sci. 2022;23(24):16226.","journal-title":"Int J Mol Sci"},{"key":"696_CR9","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40:1387\u201395.","journal-title":"Hepatology"},{"key":"696_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.alcohol.2017.07.006","volume":"66","author":"JB Whitfield","year":"2018","unstructured":"Whitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, et al. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol. 2018;66:1\u20137.","journal-title":"Alcohol"},{"issue":"4","key":"696_CR11","first-page":"912","volume":"12","author":"S Minzer","year":"2020","unstructured":"Minzer S, Losno RA, Casas R. The Effect of Alcohol on Cardiovascular Risk Factors. Is There New Information? Nutrients. 2020;12(4):912.","journal-title":"Is There New Information? Nutrients"},{"issue":"2","key":"696_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2018.10.037","volume":"70","author":"M You","year":"2019","unstructured":"You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019;70(2):237\u201348.","journal-title":"J Hepatol"},{"issue":"9","key":"696_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"29","key":"696_CR14","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"20","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med Dec. 2010;20(29):3046\u201367.","journal-title":"Stat Med Dec"},{"key":"696_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"PE","year":"1934","unstructured":"PE. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrica. 1934;26:404\u201313.","journal-title":"Biometrica"},{"issue":"7414","key":"696_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"6","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Sep. 2003;6(7414):557\u201360.","journal-title":"BMJ Sep"},{"issue":"7","key":"696_CR17","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","volume":"12","author":"J IntHout","year":"2016","unstructured":"IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open Jul. 2016;12(7):e010247.","journal-title":"BMJ Open Jul"},{"issue":"3","key":"696_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials Sep. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials Sep"},{"key":"696_CR19","volume-title":"A language and environment for statistical computing","author":"R","year":"2020","unstructured":"R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020."},{"key":"696_CR20","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","volume":"80","author":"L Chen","year":"2024","unstructured":"Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80:e64\u20136.","journal-title":"J Hepatol"},{"key":"696_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533\u201340.","journal-title":"Gut"},{"key":"696_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"CM Lee","year":"2024","unstructured":"Lee CM, Yoon EL, Kim M, Kang BK, Cho S, Nah EH, Jun DW. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79:1393\u2013400.","journal-title":"Hepatology"},{"key":"696_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K, et al. GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218\u201328.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"696_CR24","doi-asserted-by":"publisher","first-page":"155789","DOI":"10.1016\/j.metabol.2024.155789","volume":"152","author":"E Han","year":"2024","unstructured":"Han E, Lee BW, Kang ES, Cha BS, Ahn SH, Lee YH, Kim SU. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study. Metabolism. 2024;152:155789.","journal-title":"Metabolism"},{"key":"696_CR25","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.","journal-title":"Metabolism"},{"key":"696_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/jcm13041158","volume":"13","author":"T Miwa","year":"2024","unstructured":"Miwa T, Tajirika S, Imamura N, Adachi M, Horita R, Hanai T, et al. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study. J Clin Med. 2024;13:1158.","journal-title":"J Clin Med"},{"issue":"8","key":"696_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.cgh.2024.03.045","volume":"22","author":"TJ Hydes","year":"2024","unstructured":"Hydes TJ, Kennedy OJ, Glyn-Owen K, Buchanan R, Parkes J, Cuthbertson DJ, Roderick P, Byrne CD. Liver fibrosis Assessed Via Non-invasive Tests is Associated with Incident Heart Failure in a General Population Cohort. Clin Gastroenterol Hepatol. 2024;22(8):1657\u201367.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"696_CR28","doi-asserted-by":"publisher","first-page":"e0301126","DOI":"10.1371\/journal.pone.0301126","volume":"19","author":"A Kim","year":"2024","unstructured":"Kim A, Kang D, Choi SC, Cho J, Sinn DH, Gwak GY. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score. PLoS ONE. 2024;19:e0301126.","journal-title":"PLoS ONE"},{"key":"696_CR29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002778","author":"YT Chen","year":"2024","unstructured":"Chen YT, Chen TI, Yang TH, Yin SC, Lu SN, Liu XR, et al. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002778. Epub ahead of print.","journal-title":"Am J Gastroenterol"},{"key":"696_CR30","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1007\/s00261-024-04285-w","volume":"49","author":"HJ Park","year":"2024","unstructured":"Park HJ, Lee S, Lee JS. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction. AbdomRadiol (NY). 2024;49:3036\u20133044 https:\/\/doi.org\/10.1007\/s00261-024-04285-w","journal-title":"AbdomRadiol (NY)"},{"key":"696_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16552","author":"K Mori","year":"2024","unstructured":"Mori K, Akiyama Y, Tanaka M, Sato T, Endo K, Hosaka I, et al. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis. J Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1111\/jgh.16552. Epub ahead of print.","journal-title":"J Gastroenterol Hepatol"},{"key":"696_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/apt.18015","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Kimura T, Wakabayashi SI, Umemura T, Kurosaki M, Loomba R, Izumi N. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60:61\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"696_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jgh.16554","volume":"39","author":"T Wu","year":"2024","unstructured":"Wu T, Ye J, Mo S, Ye M, Li X, Li Q, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39(8):1636\u201347. . https:\/\/doi.org\/10.1111\/jgh.16554","journal-title":"J Gastroenterol Hepatol"},{"key":"696_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000925","author":"M Kwak","year":"2024","unstructured":"Kwak M, Kim HS, Jiang ZG, Yeo YH, Trivedi HD, Noureddin M, Yang JD. MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000925. Epub ahead of print.","journal-title":"Hepatology"},{"key":"696_CR35","doi-asserted-by":"publisher","first-page":"101172","DOI":"10.1016\/j.jhepr.2024.101172","volume":"6","author":"V M\u00e4nnist\u00f6","year":"2024","unstructured":"M\u00e4nnist\u00f6 V, Salomaa V, Jula A, Lundqvist A, M\u00e4nnist\u00f6 S, Perola M, et al. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population. JHEP Rep. 2024;6:101172.","journal-title":"JHEP Rep"},{"issue":"6","key":"696_CR36","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Del Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, Calleja JL, Vilar-Gomez E, Iruzubieta P, Del Rodr\u00edguez-Duque JC. Barrio Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81(6):930\u201340.","journal-title":"J Hepatol"},{"issue":"1","key":"696_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4093\/dmj.2024.0042","volume":"49","author":"R Oh","year":"2025","unstructured":"Oh R, Kim S, Cho SH, Kim J, Lee YB, Jin SM, Hur KY, Kim G, Kim JH. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality. Diabetes Metab J. 2025;49(1):80\u201391.","journal-title":"Diabetes Metab J"},{"issue":"11\u201312","key":"696_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/apt.18286","volume":"60","author":"Y Park","year":"2024","unstructured":"Park Y, Jung J, Han S, Kim GA. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study. Aliment Pharmacol Ther. 2024;60(11\u201312):1599\u2013608.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"696_CR39","first-page":"2623","volume":"34","author":"JW Baek","year":"2024","unstructured":"Baek JW, Yang YS, Jung KJ, Kimm H, Kim SY, Lee S, Jee SH. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study. NutrMetab Cardiovasc Dis. 2024;34(12):2623\u20139.","journal-title":"NutrMetab Cardiovasc Dis"},{"issue":"4","key":"696_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4143\/crt.2024.876","volume":"57","author":"T Hoang","year":"2025","unstructured":"Hoang T, Lee J, Kim BH, Cho Y, Kim J. Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 14.5-Year Cohort Study in Korea. Cancer Res Treat. 2025;57(4):1144\u201355. . https:\/\/doi.org\/10.4143\/crt.2024.876","journal-title":"Cancer Res Treat"},{"issue":"5","key":"696_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","volume":"81","author":"JH Oh","year":"2024","unstructured":"Oh JH, Ahn SB, Cho S, Nah EH, Yoon EL, Jun DW. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol. 2024;81(5):772\u201380.","journal-title":"J Hepatol"},{"issue":"8","key":"696_CR42","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.gastha.2024.08.006","volume":"3","author":"Y Kamada","year":"2024","unstructured":"Kamada Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, et al. Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants. Gastro Hep Adv. 2024;3(8):1148\u201356.","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"696_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/hepr.14133","volume":"55","author":"EL Yoon","year":"2025","unstructured":"Yoon EL, Park H, Hong HP, Lee CM, Kim M, Kang BK, Jun DW. Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population. Hepatol Res. 2025;55(3):410\u201321.","journal-title":"Hepatol Res"},{"issue":"11","key":"696_CR44","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.14309\/ajg.0000000000003321","volume":"120","author":"BV John","year":"2025","unstructured":"John BV, Bastaich D, Mezzacappa C, Ferreira RD, Hentschel A, Samos A, et al. Veterans Analysis of Liver Disease (VALID) group of investigators. Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. Am J Gastroenterol. 2025;120(11):2583\u201391. . https:\/\/doi.org\/10.14309\/ajg.0000000000003321","journal-title":"Am J Gastroenterol"},{"key":"696_CR45","doi-asserted-by":"publisher","first-page":"119161","DOI":"10.1016\/j.atherosclerosis.2025.119161","volume":"403","author":"SW Wang","year":"2025","unstructured":"Wang SW, Wang C, Cheng YM, Hsieh TH, Wang CC, Kao JH. Liver and atherosclerotic risk of alcohol consumption in patients with metabolic dysfunction-associated Steatotic Liver Disease. Atherosclerosis. 2025;403:119161.","journal-title":"Atherosclerosis"},{"issue":"4","key":"696_CR46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3803\/EnM.2024.2281","volume":"40","author":"DY Lee","year":"2025","unstructured":"Lee DY, Ko JH, Jang HN, Moon SJ, Kwon HM, Park SE, et al. Characteristics of Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Risk for Hepatic Fibrosis in 476,124 Korean Adults: A Cross-Sectional Study. Endocrinol Metab (Seoul). 2025;40(4):648\u201352. . https:\/\/doi.org\/10.3803\/EnM.2024.2281","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"696_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","volume":"83","author":"J Vaz","year":"2025","unstructured":"Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025;83(5):1011\u201322.","journal-title":"J Hepatol"},{"issue":"2","key":"696_CR48","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.aohep.2025.101919","volume":"30","author":"M Spencer-Sandino","year":"2025","unstructured":"Spencer-Sandino M, Godoy F, Huidobro L, Alvares D, Cruz F, Marco C, Garrido M, Cabrera D, Arab JP, Arrese M, Barrera F, Ferreccio C. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann Hepatol. 2025;30(2):101919.","journal-title":"Ann Hepatol"},{"key":"696_CR49","doi-asserted-by":"publisher","unstructured":"Burnside J, Cinque F, Sebastiani G, Ramji A, Patel K, Swain M, Saeed S. Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: A Canadian Longitudinal Study on Aging analysis. Can J Public Health. 2025. https:\/\/doi.org\/10.17269\/s41997-025-01025-5.","DOI":"10.17269\/s41997-025-01025-5"},{"issue":"2","key":"696_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.21037\/hbsn-24-51","volume":"14","author":"C Ong","year":"2025","unstructured":"Ong C, Tang N, Gunalan S, Teng M, Koh B, Chee D, et al. Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study. Hepatobiliary Surg Nutr. 2025;14(2):222\u201332.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"696_CR51","unstructured":"Younossi et al. Long-term mortality in steatotic liver disease is greatest in those with a combination of metabolic dysfunction and excessive alcohol consumption EASL Congress; 2025 May 7\u201310; Amsterdam, Netherlands: EASL 2025. Abstract nr 1186."},{"key":"696_CR52","doi-asserted-by":"crossref","unstructured":"Gratacos-Gines et al. ALD is diagnosed at more advanced stages of fibrosis as compared to MetALD and MASLD in the general population. EASL Congress; 2025 May 7\u201310; Amsterdam, Netherlands: EASL 2025. Abstract nr 490.","DOI":"10.1016\/S0168-8278(25)00537-9"},{"key":"696_CR53","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.jhep.2023.09.014","volume":"80","author":"D Kim","year":"2024","unstructured":"Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Metabolic dysfunction-associated steatotic liver disease and all-cause\/cause-specific mortality among adults in the United States. J Hepatol. 2024;80:e79\u201381.","journal-title":"J Hepatol"},{"key":"696_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.18011","volume":"60","author":"D Kim","year":"2024","unstructured":"Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024;60:33\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"696_CR55","first-page":"2085","volume":"34","author":"M Li","year":"2024","unstructured":"Li M, Chen W, Deng Y, Xie W. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups. NutrMetab Cardiovasc Dis. 2024;34(9):2085\u201394.","journal-title":"NutrMetab Cardiovasc Dis"},{"issue":"10","key":"696_CR56","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","volume":"6","author":"P Sripongpun","year":"2024","unstructured":"Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep. 2024;6(10):101127.","journal-title":"JHEP Rep"},{"key":"696_CR57","doi-asserted-by":"crossref","unstructured":"Zeng G, Wang P, Xu W, Li Q, Li T, Tian Y, Huang B, Grobbee D, Cabezas MC, Yuan J. Steatotic Liver Disease as a Risk Enhancer in the Presence of Metabolic Syndrome. Eur J Prev Cardiol. 2025;zwaf330.","DOI":"10.1093\/eurjpc\/zwaf330"},{"issue":"1","key":"696_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12876-025-03661-0","volume":"25","author":"Y Liang","year":"2025","unstructured":"Liang Y, Ye X, Pan M, Chen Y, Yuan Y, Luo L. Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study. BMC Gastroenterol. 2025;25(1):75.","journal-title":"BMC Gastroenterol"},{"key":"696_CR59","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020. Clin Gastroenterol Hepatol. 2024;22:1330\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"696_CR60","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3350\/cmh.2024.0987","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017\u20132023. Clin Mol Hepatol. 2025;31(2):382\u201393.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"696_CR61","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/jgh.16726","volume":"39","author":"MB Aboona","year":"2024","unstructured":"Aboona MB, Danpanichkul P, Chen VL, Rangan P, Kim D, Alkhouri N, Fallon MB, Noureddin M, Arab JP, Wijarnpreecha K. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. J Gastroenterol Hepatol. 2024;39(11):2456\u201363.","journal-title":"J Gastroenterol Hepatol"},{"key":"696_CR62","doi-asserted-by":"publisher","first-page":"1505970","DOI":"10.3389\/fnut.2024.1505970","volume":"11","author":"P Wang","year":"2025","unstructured":"Wang P, Xia B, Wang S. Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017\u20132020. Front Nutr. 2025;11:1505970.","journal-title":"Front Nutr"},{"issue":"1","key":"696_CR63","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.aohep.2025.101907","volume":"30","author":"E Kaya","year":"2025","unstructured":"Kaya E, Vilar-Gomez E, Vuppalanchi R, Yilmaz Y. Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease. Ann Hepatol. 2025;30(1):101907.","journal-title":"Ann Hepatol"},{"issue":"1","key":"696_CR64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12876-025-03912-0","volume":"25","author":"HY Peng","year":"2025","unstructured":"Peng HY, Lu CL, Zhao M, Huang XQ, Huang SX, Zhuo ZW, Liu J, Lu YP, Lv WL. Clinical characteristics of MASLD\/MetALD\/MAFLD\/NAFLD and the relative risk analysis on metabolic disorders. BMC Gastroenterol. 2025;25(1):372.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"696_CR65","doi-asserted-by":"publisher","first-page":"e70127","DOI":"10.1111\/liv.70127","volume":"45","author":"JM Paik","year":"2025","unstructured":"Paik JM, Henry L, Younossi ZM. The Global Burden of MASLD in the Past Three Decades. Liver Int. 2025;45(6):e70127.","journal-title":"Liver Int"},{"key":"696_CR66","doi-asserted-by":"publisher","first-page":"04003","DOI":"10.7189\/jogh.15.04003","volume":"15","author":"S Yan","year":"2025","unstructured":"Yan S, Li Q, Cao W, Pei H, Zhen S, Wu Q, Yang X, Liang F. Association of steatotic liver disease with all-cause and cardiovascular mortality among prehypertensive or hypertensive patients. J Glob Health. 2025;15:04003.","journal-title":"J Glob Health"},{"key":"696_CR67","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","volume":"65","author":"JH Moon","year":"2023","unstructured":"Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"696_CR68","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000535943","volume":"13","author":"GA Kim","year":"2023","unstructured":"Kim GA, Jeong S, Jang H, Lee DH, Joo SK, Kim W. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study. Liver Cancer. 2023;13(4):426\u201337.","journal-title":"Liver Cancer"},{"key":"696_CR69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejim.2024.12.036","volume":"133","author":"B Yun","year":"2025","unstructured":"Yun B, Oh J, Park H, Kim BK, Yoon JH. Optimal BMI cutoff for lean MASLD\/MetALD and adverse hepatic outcomes in East-Asian populations. Eur J Intern Med. 2025;133:141\u20134.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"696_CR70","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12876-025-03814-1","volume":"25","author":"WY Shin","year":"2025","unstructured":"Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y. Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study: MASLD, MetALD, and dementia risk. BMC Gastroenterol. 2025;25(1):308.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"696_CR71","doi-asserted-by":"publisher","first-page":"101750","DOI":"10.1016\/j.aohep.2024.101750","volume":"30","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Xu S, Hu W, Huang J, Jiang D, Na R, Yin Z, Zhang J, Chen H. Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases. Ann Hepatol. 2025;30(1):101750.","journal-title":"Ann Hepatol"},{"issue":"4","key":"696_CR72","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/dom.16186","volume":"27","author":"Y Peng","year":"2025","unstructured":"Peng Y, Wang P, Liu F, Wang X, Si C, Gong J, Zhou H, Gu J, Qin A, Song W, Song F. Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study. Diabetes Obes Metab. 2025;27(4):1940\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"696_CR73","doi-asserted-by":"publisher","first-page":"e70109","DOI":"10.1111\/liv.70109","volume":"45","author":"J Wang","year":"2025","unstructured":"Wang J, Yang R, Miao Y, Zhang X, Paillard-Borg S, Fang Z, Xu W. Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated With Accelerated Brain Ageing: A Population-Based Study. Liver Int. 2025;45(6):e70109.","journal-title":"Liver Int"},{"key":"696_CR74","doi-asserted-by":"publisher","first-page":"175628482513313","DOI":"10.1177\/17562848251331315","volume":"18","author":"K Yang","year":"2025","unstructured":"Yang K, Lee J, Han JW, Yang H, Chae SY, Chung BS, Ryu T. A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases. Th Adv Gastroenterol. 2025;18:17562848251331315. https:\/\/doi.org\/10.1177\/17562848251331315.","journal-title":"Th Adv Gastroenterol"},{"key":"696_CR75","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.17958","volume":"59","author":"CV Schneider","year":"2024","unstructured":"Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024;59:1271\u201381.","journal-title":"Aliment Pharmacol Ther"},{"key":"696_CR76","doi-asserted-by":"publisher","first-page":"1262001","DOI":"10.1155\/ije\/1262001","volume":"2025","author":"X Bao","year":"2025","unstructured":"Bao X, Zhang X, Xu D, Wang Y, Yin S, Zhang X. Risk Heterogeneity of Liver-Related Events and Extrahepatic Outcomes Across MASLD Phenotypes and Risk Stratification by Liver Fibrosis. Int J Endocrinol. 2025;2025:1262001.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"696_CR77","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1038\/s41598-025-88420-7","volume":"15","author":"Z Dai","year":"2025","unstructured":"Dai Z, Bao Z, Lin H, Yang Q, Huang J, Zhang X, Luo N, Tang H, Zhou X. Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease. Sci Rep. 2025;15(1):5595.","journal-title":"Sci Rep"},{"issue":"10","key":"696_CR78","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1093\/rheumatology\/keaf278","volume":"64","author":"OC Kwon","year":"2025","unstructured":"Kwon OC, Lee KN, Han K. Association between steatotic liver disease and risk of incident systemic sclerosis: a nationwide cohort study. Rheumatology (Oxford). 2025;64(10):5252\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"696_CR79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12876-025-03687-4","volume":"25","author":"Y Kim","year":"2025","unstructured":"Kim Y, Lee TS, Oh CM. Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults. BMC Gastroenterol. 2025;25(1):110.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"696_CR80","doi-asserted-by":"publisher","first-page":"e70087","DOI":"10.1002\/mco2.70087","volume":"6","author":"H Zeng","year":"2025","unstructured":"Zeng H, Fang L, Yang Z, Zhao X, Chen H, Xing P et al. Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study. MedComm (2020). 2025;6(2):e70087.","journal-title":"MedComm (2020)"},{"issue":"2","key":"696_CR81","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","volume":"81","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Serper M, Wang RX, Tang H, Ghandour B, Khan S, Mahmud N. Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry. Hepatology. 2025;81(2):532\u201345.","journal-title":"Hepatology"},{"issue":"2","key":"696_CR82","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.jhepr.2024.101250","volume":"7","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2024","unstructured":"Gratac\u00f3s-Gin\u00e8s J, Ari\u00f1o S, Sancho-Bru P, Bataller R, Pose E. MetALD: Clinical aspects, pathophysiology and treatment. JHEP Rep. 2024;7(2):101250.","journal-title":"JHEP Rep"},{"issue":"5","key":"696_CR83","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1111\/liv.70017","volume":"45","author":"G Ayares","year":"2025","unstructured":"Ayares G, Diaz LA, Idalsoaga F, Alkhouri N, Noureddin M, Bataller R, Loomba R, Arab JP, Arrese M. MetALD: New Perspectives on an Old Overlooked Disease. Liver Int. 2025;45(5):e70017.","journal-title":"Liver Int"},{"issue":"11","key":"696_CR84","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2468-1253(25)00187-6","volume":"10","author":"N Torp","year":"2025","unstructured":"Torp N, Bech KT, Schnefeld HL, Johansen S, Hansen CD, Semmler G et al. Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10(11):975-985. https:\/\/doi.org\/10.1016\/S2468-1253(25)00187-6","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"696_CR85","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/apt.18506","volume":"61","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione F, Amangurbanova M, Yang AH, Tincopa MA, Ajmera V, Richards L, et al. Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study. Aliment Pharmacol Ther. 2025;61(6):1043\u201354. https:\/\/doi.org\/10.1111\/apt.18506.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"696_CR86","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","volume":"83","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione F, D\u00edaz LA, Ajmera V, Madamba E, Singh S, Bettencourt R, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025;83(5):1023\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.030.","journal-title":"J Hepatol"},{"issue":"5","key":"696_CR87","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","volume":"83","author":"J Vaz","year":"2025","unstructured":"Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, Grip ET, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025;83(5):1011\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019.","journal-title":"J Hepatol"},{"issue":"3","key":"696_CR88","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13679-024-00580-1","volume":"13","author":"K Sweatt","year":"2024","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward? Curr Obes Rep. 2024;13(3):584\u201395. https:\/\/doi.org\/10.1007\/s13679-024-00580-1.","journal-title":"Curr Obes Rep"},{"issue":"8","key":"696_CR89","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/nutrit\/nuac100","volume":"81","author":"Z Luo","year":"2023","unstructured":"Luo Z, Cheng J, Wang Y. Effects of the genetic variants of alcohol-metabolizing enzymes on lipid levels in Asian populations: a systematic review and meta-analysis. Nutr Rev. 2023;81(8):921\u201338. https:\/\/doi.org\/10.1093\/nutrit\/nuac100.","journal-title":"Nutr Rev"},{"key":"696_CR90","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/diagnostics15050565","volume":"15","author":"S Demirci","year":"2025","unstructured":"Demirci S, Sezer S. Fatty Liver Index vs. Biochemical\u2013Anthropometric Indices: Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease with Non-Invasive Tools. Diagnostics. 2025;15:565. https:\/\/doi.org\/10.3390\/diagnostics15050565.","journal-title":"Diagnostics"},{"key":"696_CR91","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3390\/jcm14103405","volume":"14","author":"R Bende","year":"2025","unstructured":"Bende R, Heredea D, Ra\u021biu I, Sporea I, D\u0103nil\u0103 M, \u0218irli R, Popescu A, Bende F. Association Between Visceral Adiposity and the Prediction of Hepatic Steatosis and Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J Clin Med. 2025;14:3405. https:\/\/doi.org\/10.3390\/jcm14103405.","journal-title":"J Clin Med"},{"issue":"2","key":"696_CR92","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.22350","volume":"48","author":"D van der Poorten","year":"2008","unstructured":"van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449\u201357. https:\/\/doi.org\/10.1002\/hep.22350.","journal-title":"Hepatology"},{"issue":"6","key":"696_CR93","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1159\/000521662","volume":"40","author":"LY Kam","year":"2022","unstructured":"Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, et al. Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. Dig Dis. 2022;40(6):734\u201344. https:\/\/doi.org\/10.1159\/000521662.","journal-title":"Dig Dis"},{"key":"696_CR94","doi-asserted-by":"publisher","first-page":"112924","DOI":"10.1016\/j.diabres.2025","volume":"229","author":"D Pantazopoulos","year":"2025","unstructured":"Pantazopoulos D, Gouveri E, Papazoglou D, Papanas N. GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review. Diabetes Res Clin Pract. 2025;229:112924. https:\/\/doi.org\/10.1016\/j.diabres.2025.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"696_CR95","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/biomedicines13071516","volume":"13","author":"L Chrysavgis","year":"2025","unstructured":"Chrysavgis L, Mourelatou NG, Cholongitas E. Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease. Treatment? Biomedicines. 2025;13(7):1516. https:\/\/doi.org\/10.3390\/biomedicines13071516.","journal-title":"Treatment? Biomedicines"},{"key":"696_CR96","doi-asserted-by":"publisher","first-page":"133608","DOI":"10.1016\/j.ijcard.2025.133608","volume":"439","author":"C Tognola","year":"2025","unstructured":"Tognola C, Bernasconi D, Intravaia RCM, Brioschi G, Toscani G, Algeri M, et al. Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program. Int J Cardiol. 2025;439:133608.","journal-title":"Int J Cardiol"},{"issue":"1","key":"696_CR97","doi-asserted-by":"publisher","first-page":"20714","DOI":"10.1038\/s41598-021-00020-3","volume":"11","author":"C Caselli","year":"2021","unstructured":"Caselli C, De Caterina R, Smit JM, Campolo J, El Mahdiui M, Ragusa R, Clemente A, Sampietro T, Clerico A, Liga R, Pelosi G, Rocchiccioli S, Parodi O, Scholte A, Knuuti J, Neglia D. EVINCI and SMARTool. Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina. Sci Rep. 2021;11(1):20714.","journal-title":"Sci Rep"},{"issue":"14","key":"696_CR98","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/CIRCULATIONAHA.122.061010","volume":"147","author":"MB Mortensen","year":"2023","unstructured":"Mortensen MB, Dzaye O, B\u00f8tker HE, Jensen JM, Maeng M, Bentzon JF, et al. Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry. Circulation. 2023;147(14):1053\u201363.","journal-title":"Circulation"},{"issue":"10","key":"696_CR99","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1161\/HYPERTENSIONAHA.123.21224","volume":"80","author":"S Di Federico","year":"2023","unstructured":"Di Federico S, Filippini T, Whelton PK, Cecchini M, Iamandii I, Boriani G, Vinceti M. Alcohol Intake and Blood Pressure Levels: A Dose-Response Meta-Analysis of Nonexperimental Cohort Studies. Hypertension. 2023;80(10):1961\u20139.","journal-title":"Hypertension"},{"issue":"1","key":"696_CR100","doi-asserted-by":"publisher","first-page":"21869","DOI":"10.1038\/s41598-022-25653-w","volume":"12","author":"EM Siegmann","year":"2022","unstructured":"Siegmann EM, Mazza M, Weinland C, Kiefer F, Kornhuber J, M\u00fchle C, et al. Meta-analytic evidence for a sex-diverging association between alcohol use and body mass index. Sci Rep. 2022;12(1):21869.","journal-title":"Sci Rep"},{"key":"696_CR101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.alcohol.2020.02.166","volume":"86","author":"A Silczuk","year":"2020","unstructured":"Silczuk A, Habrat B. Alcohol-induced thrombocytopenia: Current review. Alcohol. 2020;86:9\u201316.","journal-title":"Alcohol"},{"issue":"17","key":"696_CR102","doi-asserted-by":"publisher","first-page":"8328","DOI":"10.3390\/ijms26178328","volume":"26","author":"T Tadokoro","year":"2025","unstructured":"Tadokoro T, Oura K, Nakahara M, Fujita K, Tani J, Morishita A, Kobara H. Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations. Int J Mol Sci. 2025;26(17):8328.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"696_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13105-023-00991-z","volume":"80","author":"AM Kaneva","year":"2024","unstructured":"Kaneva AM, Bojko ER. Fatty liver index (FLI): more than a marker of hepatic steatosis. J Physiol Biochem. 2024;80(1):11\u201326.","journal-title":"J Physiol Biochem"},{"issue":"4","key":"696_CR104","doi-asserted-by":"publisher","first-page":"e100319","DOI":"10.1136\/egastro-2025-100319","volume":"3","author":"B Gao","year":"2025","unstructured":"Gao B, Arab JP, Liangpunsakul S, Ding WX, Szabo G, Mehal W, Wang H, He Y, St\u00e4rkel P, Llorente C, Schnabl B, Hwang S, Vandermerwe S, Gao Y, Zheng MH, Kim W, George J, Bataller R, Loomba R, Leggio L, Tacke F. Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology. 2025;3(4):e100319.","journal-title":"eGastroenterology"},{"issue":"10","key":"696_CR105","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/apt.70281","volume":"62","author":"N Torp","year":"2025","unstructured":"Torp N, Israelsen M, Johansen S, Semmler G, Dalby Hansen C, Bech KT, et al. MetALD: Diagnosis and Prognosis With Non-Invasive Tests. Aliment Pharmacol Ther. 2025;62(10):990\u20131002.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"696_CR106","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.pcad.2018.02.001","volume":"61","author":"EL O\u2019Keefe","year":"2018","unstructured":"O\u2019Keefe EL, DiNicolantonio JJ, O\u2019Keefe JH, Lavie CJ. Alcohol and CV Health: Jekyll and Hyde J-Curves. Prog Cardiovasc Dis. 2018;61(1):68\u201375.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"696_CR107","doi-asserted-by":"publisher","first-page":"219","DOI":"10.35946\/arcr.v38.2.06","volume":"38","author":"MR Piano","year":"2017","unstructured":"Piano MR. Alcohol\u2019s Effects on the Cardiovascular System. Alcohol Res. 2017;38(2):219\u201341.","journal-title":"Alcohol Res"},{"issue":"4","key":"696_CR108","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab JP, D\u00edaz LA, Rehm J, Im G, Arrese M, Kamath PS, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82(4):744\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.028.","journal-title":"J Hepatol"},{"key":"696_CR109","doi-asserted-by":"publisher","first-page":"1670769","DOI":"10.3389\/ftox.2025.1670769","volume":"7","author":"J Lee","year":"2025","unstructured":"Lee J, Lee JY, Kang H. Excessive alcohol consumption: a driver of metabolic dysfunction and inflammation. Front Toxicol. 2025;7:1670769. https:\/\/doi.org\/10.3389\/ftox.2025.1670769.","journal-title":"Front Toxicol"},{"issue":"3","key":"696_CR110","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13679-024-00560-5","volume":"13","author":"D Mart\u00ednez-Urbistondo","year":"2024","unstructured":"Mart\u00ednez-Urbistondo D, Perez-Diaz-Del-Campo N, Landecho MF, Mart\u00ednez JA. Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks. Curr Obes Rep. 2024;13(3):461\u201374. https:\/\/doi.org\/10.1007\/s13679-024-00560-5.","journal-title":"Curr Obes Rep"},{"issue":"1","key":"696_CR111","doi-asserted-by":"publisher","first-page":"e001629","DOI":"10.1136\/bmjdrc-2020-001629","volume":"8","author":"T Okamura","year":"2020","unstructured":"Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Effect of alcohol consumption and the presence of fatty liver on the risk for incident type 2 diabetes: a population-based longitudinal study. BMJ Open Diabetes Res Care. 2020;8(1):e001629.","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00696-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:29:48Z","timestamp":1781638188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00696-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00696-6","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"19"}}